Cue Biopharma Inc.

14.50-0.4100-2.75%Vol 261.94K1Y Perf -4.34%
Sep 24th, 2021 16:00 DELAYED
BID14.50 ASK14.56
Open14.87 Previous Close14.91
Pre-Market- After-Market-
 - -  - -%
Target Price
29.00 
Analyst Rating
Strong Buy 1.00
Potential %
100.00 
Finscreener Ranking
★★★★★     61.24
Insiders Trans % 3/6/12 mo.
-/-/-11 
Value Ranking
★★★     50.58
Insiders Value % 3/6/12 mo.
-/-/-33 
Growth Ranking
★★★★+     62.70
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-31 
Income Ranking
 —    -
Price Range Ratio 52W %
63.98 
Earnings Rating
Neutral
Market Cap456.87M 
Earnings Date
16th Nov 2021
Alpha-0.01 Standard Deviation0.21
Beta1.78 

Today's Price Range

14.2615.21

52W Range

9.6517.23

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
12.32%
1 Month
23.51%
3 Months
7.73%
6 Months
18.08%
1 Year
-4.34%
3 Years
60.58%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CUE14.50-0.4100-2.75
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.42-0.3321.43
Q01 2021-0.37-0.41-10.81
Q04 2020-0.33-0.37-12.12
Q03 2020-0.37-0.348.11
Q02 2020-0.41-0.387.32
Q01 2020-0.32-0.48-50.00
Q04 2019-0.42-0.3711.90
Q03 2019-0.44-0.3129.55
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.39-2.63Negative
12/2021 QR-0.2417.24Positive
12/2021 FY-1.344.29Positive
12/2022 FY-1.68-5.66Negative
Next Report Date16th Nov 2021
Estimated EPS Next Report-0.39
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume261.94K
Shares Outstanding31.51M
Shares Float30.51M
Trades Count2.69K
Dollar Volume5.27M
Avg. Volume335.95K
Avg. Weekly Volume397.25K
Avg. Monthly Volume292.71K
Avg. Quarterly Volume227.36K

Cue Biopharma Inc. (NASDAQ: CUE) stock closed at 14.5 per share at the end of the most recent trading day (a -2.75% change compared to the prior day closing price) with a volume of 262.04K shares and market capitalization of 456.87M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Cue Biopharma Inc. CEO is Daniel R. Passeri.

The one-year performance of Cue Biopharma Inc. stock is -4.34%, while year-to-date (YTD) performance is 15.91%. CUE stock has a five-year performance of %. Its 52-week range is between 9.65 and 17.23, which gives CUE stock a 52-week price range ratio of 63.98%

Cue Biopharma Inc. currently has a PE ratio of -9.00, a price-to-book (PB) ratio of 5.58, a price-to-sale (PS) ratio of 76.19, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.98%, a ROC of -53.05% and a ROE of -57.39%. The company’s profit margin is -%, its EBITDA margin is -781.90%, and its revenue ttm is $5.47 Million , which makes it $0.17 revenue per share.

Of the last four earnings reports from Cue Biopharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.39 for the next earnings report. Cue Biopharma Inc.’s next earnings report date is 16th Nov 2021.

The consensus rating of Wall Street analysts for Cue Biopharma Inc. is Strong Buy (1), with a target price of $29, which is +100.00% compared to the current price. The earnings rating for Cue Biopharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cue Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cue Biopharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.28, ATR14 : 0.95, CCI20 : 174.51, Chaikin Money Flow : 0.09, MACD : 0.79, Money Flow Index : 76.68, ROC : 25.76, RSI : 68.98, STOCH (14,3) : 74.49, STOCH RSI : 0.65, UO : 57.27, Williams %R : -25.51), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cue Biopharma Inc. in the last 12-months were: Aaron Fletcher (Buy at a value of $82 776), Anish Suri (Option Excercise at a value of $0), Cameron Gray (Buy at a value of $151 500), Kenneth J. Pienta (Buy at a value of $40 980), Kenneth J. Pienta (Option Excercise at a value of $139 365), Kenneth J. Pienta (Sold 36 433 shares of value $550 641 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers.

CEO: Daniel R. Passeri

Telephone: +1 617 949-2680

Address: 21 Erie Street, Cambridge 02139, MA, US

Number of employees: 47

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

61%39%

Bearish Bullish

56%44%

News

Stocktwits